Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

PHASE1CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions

Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women

Interventions

DRUG

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

DRUG

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Trial Locations (5)

DeLand

Orlando

Miami

San Antonio

Anaheim